Contact Us
Drug Search Results
More Filters [+]

Rintatolimod

Alternative Names: rintatolimod, Ampligen
Latest Update: 2024-12-17
Latest Update Note: News Article

Product Description

Mechanisms of Action: TLR3 Agonist

Novel Mechanism: Yes

Modality: Nucleic Acid

Route of Administration: Intravenous

FDA Designation:
Orphan Drug - Hemorrhagic Fever, Ebola
Orphan Drug - Pancreatic Cancer *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AIM ImmunoTech
Company Location: OCALA FL 32801
Company CEO: Thomas K. Equels
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Rintatolimod

Countries in Clinic: Netherlands, United States

Active Clinical Trial Count: 5

Highest Development Phases

Phase 2: Adenocarcinoma|Pancreatic Cancer|Post Acute COVID-19 Syndrome|Prostate Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2024-518627-29-00

P2

Unknown Status

Pancreatic Cancer

2028-07-01

AMP-270

P2

Recruiting

Pancreatic Cancer

2028-06-01

Randomized Phase 2 Study

P2

Suspended

Adenocarcinoma|Prostate Cancer

2026-05-29

DURIPANC

P2

Recruiting

Pancreatic Cancer|Adenocarcinoma

2026-04-01

Recent News Events

Date

Type

Title

12/17/2024

News Article

 AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

12/17/2024

News Article

 AIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual Meeting

12/16/2024

News Article

 AIM ImmunoTech Reminds Shareholders to Vote "FOR" All Four Incumbent Board Members on the WHITE Universal Proxy Card

12/12/2024

News Article

 AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue

04/12/2024

PubMed

 Antiviral Chemotherapy in Avian Medicine-A Review.

03/15/2024

PubMed

 Rintatolimod in Advanced Pancreatic Cancer enhances Anti-Tumor Immunity through Dendritic Cell-Mediated T Cell Responses.

11/01/2023

PubMed

 Systemic infusion of TLR3-ligand and IFN-α in patients with breast cancer reprograms local tumor microenvironments for selective CTL influx.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions